Here are five key notes:
1. More than 40 children were given a three-day oral wheat challenge, at which point their immune response was analyzed.
2. The study found that T cell recognition of wheat gluten epitopes in children with celiac disease did not differ significantly from that of adults.
3. According to study author Jason Tye-Din, PhD, this result indicates that “diagnostic tools and treatments currently being developed may be applicable in celiac disease patients of all ages.”
4. ImmusanT, privately held biotechnology company, announced the publication of the article.
5. The company is the developer of the Nexvax2, a disease-modifying immunotherapy.
More articles on GI/endoscopy:
Dr. Ayan Rage joins Essentia Health
AGA: 8 things to know about celiac disease
To stay or go? When GI physicians consider changing practice settings
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.